Filing Details

Accession Number:
0001567619-21-017771
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-01 19:39:15
Reporting Period:
2021-09-30
Accepted Time:
2021-10-01 19:39:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1626971 Corvus Pharmaceuticals Inc. CRVS () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1587114 Ecor1 Capital, Llc 357 Tehama Street #3
San Francisco CA 94103
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-09-30 3,000,000 $5.04 2,081,077 No 4 S Indirect See Note 2
Common Stock Disposition 2021-10-01 2,000,000 $4.96 81,077 No 4 S Indirect See Note 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Note 2
No 4 S Indirect See Note 2
Footnotes
  1. EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction.
  2. The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
  3. Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction.